Top

News & Events

Clinigen signs agreement with Nordic Pharma for aprotinin

Clinigen signs agreement with Nordic Pharma for aprotinin

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has signed an agreement with Nordic Pharma Ltd. (‘Nordic Pharma’) to manage the supply and distribution of aprotinin in a range of countries in Asia Pacific and South Africa.

Aprotinin Injection belongs to a group of medicines called anti-fibrinolytics (medicines to prevent blood loss). Aprotinin can help to reduce blood loss and the need for blood transfusions during isolated cardiopulmonary bypass graft surgery.

Under the terms of this agreement, Clinigen will make aprotinin available to physicians and pharmacists on an unlicensed, on-demand basis for patients who lack other suitable therapeutic options in a number of countries. The contract grants Clinigen the exclusive rights to supply aprotinin in Australia, New Zealand, Japan, Singapore, Malaysia, Taiwan, Thailand, Hong Kong and South Africa.

Julie Gosper, Head of Global Access, Clinigen, said:

“This agreement demonstrates Clinigen’s ongoing commitment to providing physicians and pharmacists with the access to medicines they require to address patients’ unmet medical needs. We look forward to working with the Nordic Pharma team to enable broader access to this important product.”

Hans Schram, CEO, Nordic Pharma, said:

“Nordic Pharma is committed to improving the access to aprotinin worldwide, which is an important lifesaving product in the arsenal of patient blood management. This collaboration with Clinigen will improve access to this medicine in a number of territories where it is currently not commercially available.”

Healthcare professionals can obtain details about aprotinin by emailing medicineaccess@clinigengroup.com

About Aprotinin
Aprotinin is licensed in the UK for prophylactic use to reduce blood loss and blood transfusion in adult patients who are at high risk of major blood loss undergoing isolated cardiopulmonary bypass graft surgery (i.e. coronary artery bypass graft surgery that is not combined with other cardiovascular surgery).

Aprotinin should only be used after careful consideration of the benefits and risks, and the consideration that alternative treatments are available.

About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com

About Nordic Group B.V.
Nordic Group B.V. is a privately-owned pan-European specialty pharmaceutical company with a direct presence in 17 European countries. The company focuses on the development and commercialization of niche hospital and orphan products, aiming to address unmet medical needs in rheumatology, gynecology and critical care. Nordic focuses on the development and sales of its own products, while exploring product opportunities throughout the various stages of product development.

The Nordic Group has always maintained a tradition of developing successful partnerships with third parties, in addition to supporting internal development projects. Nordic also offers U.S., Japanese, and other non-European companies the opportunity to take advantage of Nordic's intricate understanding of the European markets by forging broad partnerships to develop, register, and commercialize their products in Europe.

Find more information at www.nordicpharmagroup.com

Issued for and on behalf of Clinigen Group plc by Instinctif Partners.
For more information please contact clinigen@instinctif.com

 


 



People


Melanie Toyne-Sewell
Managing Partner


Melanie Toyne-Sewell
Managing Partner